logo
logo
AVTR stock ticker logo

Avantor, Inc.

NYSE•AVTR
CEO: Mr. Michael Stubblefield
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2019-05-17
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
連絡先情報
Radnor Corporate Center, Building One Suite 200 100 Matsonford Road, Radnor, PA, 19087, United States
610-386-1700
www.avantorsciences.com
時価総額
$5.32B
PER (TTM)
-10.0
34.6
配当利回り
--
52週高値
$17.11
52週安値
$7.58
52週レンジ
2%
順位45Top 56.8%
3.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.66B+0.00%
直近4四半期の推移

EPS

$0.08+0.00%
直近4四半期の推移

フリーCF

$117.20M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Sales Decline 3.4% Net sales totaled $6,552.2M USD, down 3.4% from prior year; organic sales decreased 2.8% USD.
Goodwill Impairment Recorded Recorded $785.0M non-cash goodwill impairment charge in Q3 2025 impacting Distribution reporting unit valuation.
Strong Liquidity Position Maintained Total liquidity reached $1,745.9M USD at year-end, supported by $1,380.5M unused credit facility availability.
Share Repurchase Authorization Board authorized $500.0M common stock repurchase program in October 2025; $75.0M executed in Q4 2025.

リスク要因

Operating Results Deterioration Operating loss reached $(246.2)M USD, a $1,331.0M decline, driven by impairment and lower gross profit.
Supply Chain Inflation Pressures Experienced inflationary pressures across cost categories; pricing and productivity measures may not fully offset adverse impact.
Customer Demand Slowdown Laboratory Solutions sales declined due to reduced demand for consumables and increased competitive intensity in end markets.
Regulatory Compliance Exposure Subject to complex and evolving global laws regarding data privacy, trade, and environmental compliance; failure risks material impact.

見通し

Cost Transformation Initiative Expanded Cost transformation initiative expanded; now targeting $400M in run rate gross savings by the end of 2027.
Future Segment Realignment Planned Intends to implement new operating model effective January 1, 2026, with two segments: VWR Distribution & Services.
Focus on Innovation Model Continue investing in differentiated innovation model, enhancing product purity and developing new products in cell and gene therapy.
No Cash Dividends Expected Currently do not expect to pay cash dividends on common stock due to debt agreements limiting distributions.

同業比較

売上高 (TTM)

MOH stock ticker logoMOH
$45.43B
+11.7%
HSIC stock ticker logoHSIC
$13.18B
+4.0%
BAX stock ticker logoBAX
$11.24B
+5.7%

粗利益率 (最新四半期)

MASI stock ticker logoMASI
60.0%
+9.9pp
BIO stock ticker logoBIO
49.8%
-2.2pp
RGEN stock ticker logoRGEN
47.2%
+3.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
MASI$9.45B-62.3-17.2%32.9%
BAX$9.07B-9.5-13.8%48.8%
HSIC$8.81B22.111.9%32.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.7%
緩やかな成長
4四半期純利益CAGR
-6.7%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月23日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし